|Bid||7.90 x 1800|
|Ask||7.89 x 900|
|Day's Range||7.69 - 7.95|
|52 Week Range||2.87 - 11.70|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2023 - Mar 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.33|
Subscribe to Yahoo Finance Plus to view Fair Value for BLUE
Investing in small-cap stocks can be very risky. Let's consider two small-cap stocks that carry above-average risk but that could soar as early as next year if things work out: Bluebird Bio (NASDAQ: BLUE) and Krystal Biotech (NASDAQ: KRYS). Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses.
Bluebird Bio Inc (NASDAQ: BLUE) has agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million. Bluebird was granted two PRVs upon the FDA approvals of Zynteglo (betibeglogene autotemcel) for beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and Skysona (elivaldogene autotemcel) for early, active cerebral adrenoleukodystrophy. "As momentum builds across our business, this non-dilutive capital further bolsters the ongoing la
SOMERVILLE, Mass., November 30, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million.